CrowdStrike’s analyst fair value estimate has shifted from about US$546.89 to about US$490.48, a move that puts the modeled upside closer to the pack of Street price targets in the mid US$400s to low ...
Royalty Pharma’s updated fair value price target now sits at US$51.56, compared with the previous US$51.00 level. Analysts linking this shift to current Street commentary point to optimism around the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results